ClinicalTrials.gg
RecruitingNCT06878950GAINUpdated Mar 17, 2026

Early Feeds in Gastroschisis

An interventional study of Early Feeding Protocol in Gastroschisis, sponsored by University of California, Davis. Recruiting at 2 sites in United States. Open to participants aged 0 Days to 1 Year. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by University of California, Davis · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
0 Days to 1 Year
Sex
All
01

Study summary

This study aims to evaluate the feasibility of initiating early feeds in neonates with gastroschisis, a condition where infants are born with their intestines outside the body.

02

Conditions studied

  • Gastroschisis

Browse trials for

Keywords

  • Gastroschisis
  • Early feeds in Gastroschisis
03

In context

Gastroschisis

42 studies on the registry are indexed under Gastroschisis; 6 are open to participants now.

This study's planned enrollment of 20 is below the median of 44 across 26 interventional studies indexed under Gastroschisis.

Browse Gastroschisis studies →

Lead sponsor

University of California, Davis is the lead sponsor of 809 studies on the registry; 142 are open to participants now.

Of its 67 completed or terminated interventional studies of FDA-regulated products, 43 (64%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 1 Year
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates with presumed simple gastroschisis
  • Born at ≥ 34 weeks' gestation
  • Hemodynamically stable
  • Consented within 48 hours after abdominal closure
  • Mothers who are ≥16 years old
  • Mothers who speak English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Neonates with evidence of complex gastroschisis at time of closure (any ischemic bowel, intestinal perforation, or obvious atresia with mesenteric defect)
  • Presence of any major congenital anomalies
  • Neonates who are receiving ionotropic medications
  • Neonates who are wards of the state
  • Neonates whose care is considered to be futile or those undergoing re-direction of care
  • Neonates participating in another interventional trial
  • Any patient deemed unfit for participation by study investigator(s)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Early Feeding Protocol Group

    This arm involves neonates with presumed simple gastroschisis who will be subjected to an early feeding protocol. The protocol specifies initiating human milk feeds within 48 hours of surgical repair of gastroschisis. Feeds are advanced based on tolerance and clinical assessment, with a focus on promoting oral motor skill development.

    Procedure: Early Feeding Protocol

Interventions

  • ProcedureEarly Feeding Protocol

    The intervention includes removal of Replogle within 24 hours of abdominal closure and the initiation of introductory feeds within 48 hours of abdominal closure.

    Also known as: Early Initiation of Human Milk Feeds

06

What researchers measure

Primary outcomes

  1. Feasibility of Enrollment in Early Feeding Study Cohort

    Proportion of eligible neonates with gastroschisis whose parents/guardians consent to enrollment in the study.

    Time frame: From prenatal period within the first 24 hours of abdominal closure

Secondary outcomes

  1. Feasibility of Protocol Adherence

    Proportion of enrolled neonates who are initiated on introductory feeds within 48 hours of abdominal closure.

    Time frame: From abdominal closure to 48 hours after closure.

  2. Fidelity to Protocol

    Proportion of enrolled infants with gastroschisis who adhere to the remainder of the protocol without major deviations. Feasibility will be assessed using protocol adherence tracking forms completed by study team.

    Time frame: From abdominal closure through discharge from the hospital, average of 90 days

  3. Protocol Withdrawal Rate

    Proportion of enrolled infants who withdraw from the study

    Time frame: From time of enrollment (prenatal) to hospital discharge, an average of 90 days

Other outcomes

  1. Outcomes of of Adverse Events

    This exploratory outcome is measuring the incidence of severe adverse events in neonates enrolled in the early feeding protocol study. Adverse events include: * Necrotizing enterocolitis (\>Stage II) * Sepsis * Abdominal compartment syndrome * Additional abdominal surgeries (excluding primary closure) * Mortality

    Time frame: From enrollment through hospital discharge, an average of 90 days

  2. Outcomes of Hospital Admission Duration

    This exploratory outcome measures the total duration of length (days) of hospital stay.

    Time frame: From birth admission to hospital through discharge, assessed up to 1 year

  3. Outcome of Duration of Parenteral Nutrition

    This exploratory outcome measures the total duration of parenteral nutrition (days) in enrolled patients.

    Time frame: From initiation of parenteral nutrition through achievement of enteral autonomy, assessed up to 1 year

  4. Outcome of Feeding Progression

    This exploratory outcome measures the feeding progression (time to first feed (days) and time to full feeds (days)) in infants enrolled.

    Time frame: From initiation of feeds through achievement of enteral autonomy, assessed up to 1 year

  5. Outcome of Growth Parameters

    This exploratory outcomes measures the changes in growth parameters (height, weight) using calculated z-scores (as measured by standard deviations from the mean, presented in percentages relative to average for age).

    Time frame: From birth admission to hospital through discharge, assessed up to 1 year

  6. Feasibility of Data Collection of Direct Breastfeeding Practices

    Assessment of the feasibility of obtaining information related to breastfeeding practices through electronic medical records, using dichotomous measures of whether parent had direct breastfeeding during hospitalization and at time of discharge (48 hours prior to hospital discharge).

    Time frame: Assessed from birth through hospital discharge, an average of 90 days

07

Study locations

1 of 2 sites recruiting
08

References and documents

Publications

  • Hobson D, Spence K, Trivedi A, Thomas G. Differences in attitudes to feeding post repair of Gastroschisis and development of a standardized feeding protocol. BMC Pediatr. 2019 Dec 4;19(1):475. doi: 10.1186/s12887-019-1858-z. PubMed 31801489 ↗
  • DeUgarte DA, Calkins KL, Guner Y, Kim J, Kling K, Kramer K, Lee H, Lusk L, Saadai P, Uy C, Rottkamp C; University of California Fetal Consortium. Adherence to and outcomes of a University-Consortium gastroschisis pathway. J Pediatr Surg. 2020 Jan;55(1):45-48. doi: 10.1016/j.jpedsurg.2019.09.048. Epub 2019 Oct 27. PubMed 31704046 ↗
  • Jyoti J, James-Nunez K, Spence K, Parkinson B, Thomas G, Trivedi A. Evaluation of gastroschisis feeding protocol: A retrospective cohort study. J Paediatr Child Health. 2024 Nov;60(11):675-679. doi: 10.1111/jpc.16657. Epub 2024 Aug 29. PubMed 39206671 ↗
  • Cacho NT, Cera AJ, Tancredi DJ, Wieck MM, Anderson JE, Leegwater AJ, Uy CC, Guner YS, DeUgarte DA, Rosenthal JL, Calkins KL, Bautista GM; University of California Fetal Consortium (UCfC). GAIN: a multicenter pilot protocol for early initiation of enteral feeds in neonates with simple gastroschisis. Pilot Feasibility Stud. 2026 Jun 15. doi: 10.1186/s40814-026-01860-4. Online ahead of print. PubMed 42298737 ↗

Individual participant data

Plan to share: Yes — After the primary study results are published, individual participant data will be de-identified and made available to qualified researchers upon request, subject to a data use agreement and review by the study team. Access will be granted within 12 months of a successful application, provided the request aligns with the study's scientific objectives, the intended study is IRB approved and adheres to ethical data protection guidelines.

Supporting information: Study protocol, Informed consent form

Time frame: Starting 6 months after publication

Access criteria: The study team will review application requests submitted by interested researchers. The intended study must align with our study's scientific objectives, be IRB approved, and adhere to ethical data protection guidelines.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06878950
Collaborators
The Gerber Foundation, University of California, Los Angeles, University of California Fetal Consortium, National Center for Advancing Translational Sciences (NCATS)
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Feb 24, 2025
Primary completion
Feb 1, 2028 (estimated)
Completion
Feb 1, 2029 (estimated)
Last update
Mar 17, 2026

Study contacts

Nicole Cacho, DO
Contact
ntcacho@ucdavis.edu
(916) 282-2507
Geoanna Bautista, MD
Contact
gmbautista@ucdavis.edu
(916) 282-2507
Nicole Cacho, DO
principal investigator · University of California, Davis
Geoanna Bautista, MD
principal investigator · University of California, Davis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion